Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial

Cuc Do, O. Giles Best, Lauren Thurgood, Anya Hotinski, Sinoula Apostolou, Stephen P. Mulligan, Karen Lower, Bryone Kuss

Research output: Contribution to journalArticlepeer-review

Abstract

The clinical significance of low-frequency deletions of 17p13 [tumour protein p53 (TP53)] in patients with chronic lymphocytic leukaemia (CLL) is currently unclear. Low-frequency del17p clones (<25%) were identified in 15/95 patients in the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial. Patients with low del17p, without tumour protein p53 (TP53) mutation, had significantly longer progression-free survival and overall survival durations than patients with high del17p clones. In 11/15 cases with low-frequency del17p, subclones solely with del17p or del13q were also noted. These data suggest that low-frequency del17p does not necessarily confer a poor outcome in CLL and challenges the notion of del13q as a founding event in CLL.

Original languageEnglish
Pages (from-to)556-560
Number of pages5
JournalBritish Journal of Haematology
Volume193
Issue number3
DOIs
Publication statusPublished - May 2021

Keywords

  • CLL
  • CLL FISH
  • CLL TP53
  • Leukaemia
  • Lymphoma
  • chronic lymphocytic leukaemia

Fingerprint

Dive into the research topics of 'Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial'. Together they form a unique fingerprint.

Cite this